Literature DB >> 18577635

Retinopathy of prematurity in South Africa: an assessment of needs, resources and requirements for screening programmes.

S Varughese1, C Gilbert, C Pieper, C Cook.   

Abstract

AIMS: Retinopathy of prematurity (ROP) is a major cause of blindness in children in middle-income countries. In 1995, it accounted for 10.6% of blindness in children in schools for the blind in South Africa. This study was undertaken to estimate the number of premature babies at risk and to investigate policies, practices and screening programmes.
MATERIALS AND METHODS: 17 level 1-3 neonatal units were visited in four provinces. Published literature reports were reviewed and staff interviewed.
RESULTS: 13,000-15,000 surviving premature babies are at risk of ROP each year. Shortage of equipment precluded continuous oxygen monitoring in public units. Nursing levels were often below recommendations, and most nurses were unaware of target oxygen saturations. Private units were well staffed and adequately equipped. Ophthalmologists were only visiting four units on a regular basis for screening, using the birth weight criterion of <1500 g for ROP screening. ROP needing treatment rates were low (1.6-2.9%), as were rates of follow-up.
CONCLUSIONS: Primary prevention of ROP requires meticulous neonatal care and adequately equipped and staffed units. Secondary prevention requires efficient screening and treatment programmes. Competing demands and limited resources in the public sector in South Africa have precluded prioritizing the prevention of ROP. This should be re-evaluated.

Entities:  

Mesh:

Year:  2008        PMID: 18577635     DOI: 10.1136/bjo.2008.137588

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  9 in total

1.  Retinopathy of prematurity in Africa: a systematic review.

Authors:  Daniel Wang; Roseline Duke; Rv Paul Chan; J Peter Campbell
Journal:  Ophthalmic Epidemiol       Date:  2019-03-01       Impact factor: 1.648

2.  Oxygen management among infants in neonatal units in sub-Saharan Africa: a cross-sectional survey.

Authors:  Scott K Herrod; Alex Stevenson; Yvonne E Vaucher; Scott R Lambert; Sherwin J Isenberg; Vivien L Yap; V Chinyere Ezeaka; Waldemar A Carlo
Journal:  J Perinatol       Date:  2021-03-26       Impact factor: 2.521

3.  Blindness in childhood in developing countries: time for a reassessment?

Authors:  Parikshit Gogate; Khumbo Kalua; Paul Courtright
Journal:  PLoS Med       Date:  2009-12-08       Impact factor: 11.069

4.  Pulse oximetry values of neonates admitted for care and receiving routine oxygen therapy at a resource-limited hospital in Kenya.

Authors:  Melissa C Morgan; Beth Maina; Mary Waiyego; Catherine Mutinda; Jalemba Aluvaala; Michuki Maina; Mike English
Journal:  J Paediatr Child Health       Date:  2017-10-27       Impact factor: 1.954

5.  The treatment and risk factors of retinopathy of prematurity in neonatal intensive care units.

Authors:  Yunxia Leng; Wenzhi Huang; Guoliang Ren; Cheng Cai; Qingbiao Tan; Yuqin Liang; Weizhong Yang; Zongyin Gao
Journal:  BMC Ophthalmol       Date:  2018-11-20       Impact factor: 2.209

6.  Prediction of Retinopathy of Prematurity Using the WINROP (Weight, IGF-1, Neonatal Retinopathy of Prematurity) Algorithm in a South African Population.

Authors:  Samantha Jane Kesting; Firdose Lambey Nakwa
Journal:  Front Pediatr       Date:  2022-03-23       Impact factor: 3.418

7.  Screening for retinopathy of prematurity in South of Iran.

Authors:  Mehrdad Afarid; Hamid Hosseini; Bagher Abtahi
Journal:  Middle East Afr J Ophthalmol       Date:  2012 Jul-Sep

8.  Retinopathy of prematurity in port harcourt, Nigeria.

Authors:  Adedayo O Adio; Rosemary O Ugwu; Chidi G Nwokocha; Augusta U Eneh
Journal:  ISRN Ophthalmol       Date:  2014-02-04

Review 9.  Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010.

Authors:  Hannah Blencowe; Joy E Lawn; Thomas Vazquez; Alistair Fielder; Clare Gilbert
Journal:  Pediatr Res       Date:  2013-12       Impact factor: 3.756

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.